BlackRock Amends Keros Therapeutics Stake, Passive Investment
Ticker: KROS · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Keros Therapeutics stake, still a passive play.**
AI Summary
BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating a change in its ownership of Keros Therapeutics, Inc. common stock as of December 31, 2023. This filing, an amendment number 3, shows BlackRock's updated passive investment position in the pharmaceutical company. For investors, this matters because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in its confidence or strategy regarding Keros Therapeutics, potentially influencing other investors.
Why It Matters
This filing updates BlackRock's passive ownership in Keros Therapeutics, providing transparency on a major institutional investor's position, which can influence market sentiment.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued passive interest in Keros Therapeutics, but this filing alone doesn't suggest a need for immediate action. It's a routine disclosure of an institutional holding.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person filing the SC 13G/A
- Keros Therapeutics, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No: 3' in the filing.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' and '(1)Names of reporting persons. BlackRock, Inc.'.
What is the subject company whose securities are being reported?
The subject company is Keros Therapeutics, Inc., identified under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc.' and '(Name of Issuer) Keros Therapeutics, Inc.'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified in the filing under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), indicated by the 'X' next to '[X] Rule 13d-1(b)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding Keros Therapeutics, Inc. (KROS).